Toxic proteins application in cancer therapy

Setayesh-Mehr, Zahra; Poorsargol, Mahdiye

doi:10.1007/s11033-021-06363-4

Cited by 8 publications

(7 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some major types of RIPs are trichosanthin and gelonin. 43 The action of trichosanthin has been described by Setayesh-Mehr and Poorsargol, 2021 for skin melanoma. 43 The trichosanthins was extracted from a Chinese plant and are a protein structure Type I of RIP has been assigned at 27 kDa.…”

Section: Toxic Protein S a S Ther Apeuti C S In S K In C An Cermentioning

confidence: 98%

“…Setayesh‐Mehr and Poorsargol in their paper from 2021 have reviewed the role of receptor interacting proteins (RIPs) of ribosome‐inactivating proteins as anti‐cancer therapy. They are receiving much attention in terms of anti‐cancer drugs in the research field 43 . RIPs employ the large‐size effect to block the efflux process that is governed by small drugs by drug resistance transporters, which guard against drug transfection inside cells.…”

Section: Toxic Proteins As Therapeutics In Skin Cancermentioning

confidence: 99%

See 1 more Smart Citation

Protein therapeutics as an emerging strategy to deal with skin cancer: A short review

Kulshrestha,

Goel

2023

Experimental Dermatology

View full text Add to dashboard Cite

Cancer has turned into a global menace with an exponential increase in the rate of death every year. Amongst all forms of cancers, skin cancer is the one becoming more common day by day because of the increased exposure to ultraviolet rays, chemicals, pollutants, etc. Skin cancer is of three types namely basal cell, squamous cell and melanoma which is one of the most aggressive forms of cancer with a low survival rate and easy relapse. Melanoma is also notorious for being multi‐drug resistant which accounts for its low survival rates in it. Many kinds of therapeutics are been practiced in the contemporary world, but among them, protein therapeutics is been emerging as a promising field with multiple molecular pathway targets that have revolutionized the science of oncology. Proteins acts as small‐molecule targets for cancer cells by binding to the cell surface receptors. Proteins including bromodomain and extra‐terminal domain (BET) and some toxin proteins are been tried on for dealing with melanoma targeting the major pathways including MAPK, NF‐κB and PI3K/AKT. The protein therapeutics also targets the tumour microenvironment including myofibrils, lymphatic vessels etc., thus inducing tumour cell death. In the review, several kinds of proteins and their function toward cell death will be highlighted in the context of skin cancer. In addition to this, the review will look into the inhibition of the function of other inflammatory pathways by inflammasomes and cytokines, both of which have a role in preventing cancer.

show abstract

Section: Toxic Protein S a S Ther Apeuti C S In S K In C An Cermentioning

confidence: 98%

Section: Toxic Proteins As Therapeutics In Skin Cancermentioning

confidence: 99%

Protein therapeutics as an emerging strategy to deal with skin cancer: A short review

Kulshrestha,

Goel

2023

Experimental Dermatology

View full text Add to dashboard Cite

show abstract

“…Investigations focusing on ribosome biogenesis as the therapeutic target in GBM have been conducted. Ribosome-inactivating proteins (RIPs) form a large family and are found in several plants, which inactivate the 60S ribosomal subunits and are used in chemotherapeutic agents for cancers [ 155 ]. Combination therapy with quinoin, a type 1 RIP from quinoa seeds, and temozolomide has shown synergistic cytotoxic effects in GBM cells [ 156 ].…”

Section: Ribosome Biogenesis As the Therapeutic Target For Gbmmentioning

confidence: 99%

Ribosomes and Ribosomal Proteins Promote Plasticity and Stemness Induction in Glioma Cells via Reprogramming

Hide

Shibahara

Inukai

et al. 2022

Cells

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is a lethal tumor that develops in the adult brain. Despite advances in therapeutic strategies related to surgical resection and chemo-radiotherapy, the overall survival of patients with GBM remains unsatisfactory. Genetic research on mutation, amplification, and deletion in GBM cells is important for understanding the biological aggressiveness, diagnosis, and prognosis of GBM. However, the efficacy of drugs targeting the genetic abnormalities in GBM cells is limited. Investigating special microenvironments that induce chemo-radioresistance in GBM cells is critical to improving the survival and quality of life of patients with GBM. GBM cells acquire and maintain stem-cell-like characteristics via their intrinsic potential and extrinsic factors from their special microenvironments. The acquisition of stem-cell-like phenotypes and aggressiveness may be referred to as a reprogramming of GBM cells. In addition to protein synthesis, deregulation of ribosome biogenesis is linked to several diseases including cancer. Ribosomal proteins possess both tumor-promotive and -suppressive functions as extra-ribosomal functions. Incorporation of ribosomes and overexpression of ribosomal protein S6 reprogram and induce stem-cell-like phenotypes in GBM cells. Herein, we review recent literature and our published data on the acquisition of aggressiveness by GBM and discuss therapeutic options through reprogramming.

show abstract

“…[13][14][15][16] As a special family of cytotoxic polypeptides, ribosome-inactivating proteins (RIPs) exert anticancer activity by binding to large ribosomal subunits and irreversibly inhibiting protein synthesis. 17,18 Gelonin, a type I RIP with N-glycosidase enzymatic activity, shows unrivalled efficacy in killing cells by cleaving 28S rRNA. 19 However, it has been reported that gelonin significantly inhibits protein synthesis in cell-free systems but has little inhibitory effect on intact cells with plasma mem- † Electronic supplementary information (ESI) available.…”

Section: Introductionmentioning

confidence: 99%

Biosynthesized tumor acidity and MMP dual-responsive plant toxin gelonin for robust cancer therapy

Ding,

Cao,

Zhu

et al. 2024

Biomater. Sci.

View full text Add to dashboard Cite

show abstract

Toxic proteins application in cancer therapy

Cited by 8 publications

References 92 publications

Protein therapeutics as an emerging strategy to deal with skin cancer: A short review

Protein therapeutics as an emerging strategy to deal with skin cancer: A short review

Ribosomes and Ribosomal Proteins Promote Plasticity and Stemness Induction in Glioma Cells via Reprogramming

Biosynthesized tumor acidity and MMP dual-responsive plant toxin gelonin for robust cancer therapy

Contact Info

Product

Resources

About